These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17894106)

  • 1. High dosage piperacetazine (Quide) in ambulatory schizophrenic patients--therapeutic efficacy and toxicity.
    Donlon PT; Rada RT
    Dis Nerv Syst; 1974 May; 35(5):231-6. PubMed ID: 17894106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacetazine in ambulatory chronic schizophrenic patients.
    Rada RT; Donlon PT
    Curr Ther Res Clin Exp; 1974 Feb; 16(2):124-9. PubMed ID: 4156665
    [No Abstract]   [Full Text] [Related]  

  • 3. Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients.
    Gallant DM; Mielke D; Bishop G; Oelsner T; Guerrero-Figueroa R
    Dis Nerv Syst; 1975 Apr; 36(4):193-6. PubMed ID: 1090427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High vs standard dosage fluphenazine HCL in acute schizophrenia.
    Donlon PT; Meadow A; Tupin JP; Wahba M
    J Clin Psychiatry; 1978 Nov; 39(11):800-4. PubMed ID: 363702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
    Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
    Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
    Hornung WP; Buchkremer G; Redbrake M; Klingberg S
    Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An uncontrolled clinical study with piperacetazine in the maintenance treatment of chronic schizophrenic patients.
    Amin MM; Brahm E; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1977 Jul; 13(3):10-1. PubMed ID: 18753
    [No Abstract]   [Full Text] [Related]  

  • 9. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal symptoms after long-term treatment with low-potency neuroleptics.
    Chouinard G; Bradwejn J; Annable L; Jones BD; Ross-Chouinard A
    J Clin Psychiatry; 1984 Dec; 45(12):500-2. PubMed ID: 6150030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do neuroleptics cause depression?
    Roy A
    Biol Psychiatry; 1984 May; 19(5):777-81. PubMed ID: 6145454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions.
    Gaebel W; Riesbeck M; Janssen B; Schneider F; Held T; Mecklenburg H; Sass H
    Eur Arch Psychiatry Clin Neurosci; 2003 Aug; 253(4):175-84. PubMed ID: 12910348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditioning in the prediction of drug withdrawal effects in chronic schizophrenic patients.
    Ban TA; Ananth JV; Lehmann HE
    Act Nerv Super (Praha); 1974 Mar; 16(1):23-33. PubMed ID: 4156144
    [No Abstract]   [Full Text] [Related]  

  • 14. The relationship between neuroleptic dosage and cognitive functioning in chronic schizophrenic patients.
    Hansen M; Paredes J; Koczapski A; Ledwidge B; Kogan C
    Clin Invest Med; 1987 Sep; 10(5):368-71. PubMed ID: 2890458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic treatment with neuroleptics. I: State of research on mechanisms of action, effectiveness and compliance in treatment of psychoses].
    Krausz M; Sorgenfrei T
    Psychiatr Prax; 1991 Jan; 18(1):9-13. PubMed ID: 1674156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mortality among chronic schizophrenic patients: a prospective 14-year follow-up study of 150 schizophrenic patients].
    Loas G; Azi A; Noisette C; Yon V
    Encephale; 2008 Jan; 34(1):54-60. PubMed ID: 18514151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High and low dose thiothixene treatment in chronic schizophrenia.
    Gardos G; Orzack MH; Finn G; Cole JO
    Dis Nerv Syst; 1974 Feb; 35(2):53-8. PubMed ID: 17894041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperacetazine (Quide): a controlled evaluation of the elixir in chronic schizophrenic patients.
    Gallant DM; Bishop MP
    Curr Ther Res Clin Exp; 1970 Jun; 12(6):387-9. PubMed ID: 4987346
    [No Abstract]   [Full Text] [Related]  

  • 20. [Depot neuroleptics in social psychiatric practice].
    Pruss U; Rose HK; Zechner A
    Psychiatr Prax; 1984 Jul; 11(4):101-8. PubMed ID: 6148764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.